Cargando…
Rethinking ME/CFS Diagnostic Reference Intervals via Machine Learning, and the Utility of Activin B for Defining Symptom Severity
Biomarker discovery applied to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a disabling disease of inconclusive aetiology, has identified several cytokines to potentially fulfil a role as a quantitative blood/serum marker for laboratory diagnosis, with activin B a recent addition. We...
Autores principales: | Lidbury, Brett A., Kita, Badia, Richardson, Alice M., Lewis, Donald P., Privitera, Edwina, Hayward, Susan, de Kretser, David, Hedger, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787626/ https://www.ncbi.nlm.nih.gov/pubmed/31331036 http://dx.doi.org/10.3390/diagnostics9030079 |
Ejemplares similares
-
Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study
por: Lidbury, Brett A., et al.
Publicado: (2017) -
Weighting of orthostatic intolerance time measurements with standing difficulty score stratifies ME/CFS symptom severity and analyte detection
por: Richardson, Alice M., et al.
Publicado: (2018) -
Biomedical Insights That Inform the Diagnosis of ME/CFS
por: Lidbury, Brett A., et al.
Publicado: (2020) -
Activin Biology After Lung Transplantation
por: Westall, Glen P., et al.
Publicado: (2017) -
Potential of Activin B as a Clinical Biomarker in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
por: Gravelsina, Sabine, et al.
Publicado: (2021)